Advertisement

Thalidomide and Analogs

  • Taturo Udagawa
  • Henk M. W. Verheul
  • Robert J. D’Amato
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Thalidomide was developed in 1958 by Chemie Grunenthal as an oral sedative. Subsequently, McBride (1) and Lenz (2) described the association between maternal usage of thalidomide and fetal limb defects. The effect of thalidomide as a teratogen was experimentally confirmed in a number of species (3–8). By the time thalidomide was withdrawn from the market in 1962, thousands of babies worldwide were estimated to have been born with thalidomide-related defects. As a consequence, the mechanism by which thalidomide causes birth defects has been intensively investigated. Nevertheless, the mechanism has remained elusive (9).

Keywords

Vascular Endothelial Growth Factor Human Microvascular Endothelial Cell Corneal Neovascularization Rabbit Cornea Lepromatous Leprosy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    McBride, W. G. (1961) Thalidomide and congenital abnormalities. Lancet 2, 1358.CrossRefGoogle Scholar
  2. 2.
    Lenz, W. (1962) Thalidomide and congenital abnormalities. Lancet 1, 45.CrossRefGoogle Scholar
  3. 3.
    Woolam, D. H. M. (1962) Thalidomide and the mouse. Br. Med. J. 2, 920.CrossRefGoogle Scholar
  4. 4.
    King, G. T. G. and Dendrick, F. J. (1962) Teratogenic effects of thalidomide in the Sprague-Dawley rat. Lancet 2, 1116.CrossRefGoogle Scholar
  5. 5.
    Somers, G. F. (1962) Thalidomide and congenital anomalies. Lancet 1, 912.PubMedCrossRefGoogle Scholar
  6. 6.
    Ehmann, B. (1963) Teratogenic effects of thalidomide. Lancet 1, 772.CrossRefGoogle Scholar
  7. 7.
    Delahunt, C. S., Kiss, N., Feldman, E., and Oakes, M. (1965) Some comparative pharmacological studies in man and the monkey with thalidomide. Toxicol. Appl. Pharmacol. 7,481.Google Scholar
  8. 8.
    Boylen, J. B., Horne, H. H., and Johnson, W. J. (1963) Teratogenic effects of thalidomide and its metabolites on the developing chick embryo. Proc. Can. Fed. Biol. Soc. 6, 12.Google Scholar
  9. 9.
    Stephens, T. D. (1988) Proposed mechanisms of action in thalidomide embryopathy. Teratology 38, 229–239.PubMedCrossRefGoogle Scholar
  10. 10.
    Gordon, B. G., Spielberg, S. P., Blake, D. A., and Balasubramanian, V. (1981) Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Natl. Acad. Sci. USA 78, 2545–2548.PubMedCrossRefGoogle Scholar
  11. 11.
    Fickenstscher, K. and Kohler, F. (1974) Teratogenicity and embryotoxicity of thalidomide and 3-aza-thalidomide in mice. Pharmacology 11, 193–198.CrossRefGoogle Scholar
  12. 12.
    Koch, H. P. and Czejka, M. J. (1986) Evidence for the intercalation of thalidomide into DNA: clue to the molecular mechanism of thalidomide teratogenicity. Z. Naturforsh. 41c, 1057–1061.Google Scholar
  13. 13.
    Schmahl, H.-J., Heger, W., and Nau, H. (1989) The enantiomers of the teratogenic thalidomide analogue EM 12: 2. Chemical stability, stereoselectivity of metabolism and renal excretion in the marmoset monkey. Toxicol. Lett. 45, 23–33.PubMedCrossRefGoogle Scholar
  14. 14.
    Helm, F.-C., Frankus, E., Friderichs, I., Graudums, I., and Flohé, L. (1981) Comparative teratological investigation of compounds structurally and pharmacologically related to thalidomide. Arzneimittelforschung 31, 941–949.PubMedGoogle Scholar
  15. 15.
    Tseng, S., Pak, G., Washenik, K., Pomeranz, M. K., and Shupack, J. L. (1996) Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J. Am. Acad. Dermatol. 35, 969–979.PubMedCrossRefGoogle Scholar
  16. 16.
    Vaisman, B. (1996) Mechanism of teratogenic action of thalidomide [letter]. Teratology 53, 283,284.Google Scholar
  17. 17.
    Ashby, J. and Tinwell, H. (1995) Is thalidomide mutagenic? Nature 375 453.Google Scholar
  18. 18.
    Jurand, A. (1966) Early changes in limb buds of chicken embryos after thalidomide treatment. J. Embryol. Exp. Morphol. 16, 289–300.PubMedGoogle Scholar
  19. 19.
    D’Amato, R. J., Loughnan, M. S., Flynn, E., and Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91, 4082–4085.PubMedCrossRefGoogle Scholar
  20. 20.
    Kenyon, B. M., Browne, F. M., Folkman, J., and D’Amato, R. J. (1997) Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. 64, 971–978.PubMedCrossRefGoogle Scholar
  21. 21.
    Seifert, R., Zhao, B., and Christ, B. (1992) Cytokinetic studies on the aortic endothelium and limb bud vascularization in avian embryos. Anat. Embryol. 186, 601–610.PubMedCrossRefGoogle Scholar
  22. 22.
    Reynolds, L. P., Killilea, S. D., and Redmer, D. A. (1992) Angiogenesis in the female reproductive system. FASEB J. 6, 886–892.PubMedGoogle Scholar
  23. 23.
    Folkman, J. and Klagsburn, M. (1987) Angiogenic factors. Science 235, 442–447.PubMedCrossRefGoogle Scholar
  24. 24.
    Engerman, R. L., Pfaffenbach, D., and Davis, M. D. (1967) Cell turnover of capillaries. Lab. lnvest. 17, 738–743.Google Scholar
  25. 25.
    Denekamp, J. (1993) Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Radiol. 66, 181–196.PubMedCrossRefGoogle Scholar
  26. 26.
    Ingber, D. Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., and Folkman, J. (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348 555–557.Google Scholar
  27. 27.
    Klauber, N., Rohan, R. M., Flynn, E., and D’Amato, R. J. (1996) Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nat. Med. 3, 443–446.CrossRefGoogle Scholar
  28. 28.
    Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27–31.PubMedCrossRefGoogle Scholar
  29. 29.
    Folkman, J. (1995) Clinical applications of research on angiogenesis. N. Engl. J. Med. 333,1757–1763.PubMedCrossRefGoogle Scholar
  30. 30.
    Blaschke, G., Kraft, H. P., Fickentscher, K., and Kohler, F. (1979) Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers. Arzneimittelforschung 29, 1640–1642.Google Scholar
  31. 31.
    Kohler, F. and Ockenfels, H. (1970) Teratogene wirkung der N-Phthalyl-DL-glutaminsaure nach intraperitonealer applikation bei der maus. Experientia 26, 1157,1158.Google Scholar
  32. 32.
    Ockenfels, H. and Kohler, F. (1970) Das L-isomere als teratogenes prinzip der N-phthalyl-DLglutaminsaure. Experientia 26, 1236, 1237.Google Scholar
  33. 33.
    Schumacher, H. Smith, R. L., and Williams, R. T. (1965) The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br. J. Pharmacol. 25 324–337.Google Scholar
  34. 34.
    Kocher-Becker, U. and Kocher, W. (1982) Teratogenic activity of a hydrolytic thalidomide metabolite in mice. Naturwissenschaften 69, 191, 192.Google Scholar
  35. 35.
    Keberle, H., Loustalot, P., Maller, R. K., Faigle, J. W., and Schmid, K. (1965) Biochemical effects of drugs on the mammalian conceptus. Ann. NYAcad. Sci. 123, 252–262.Google Scholar
  36. 36.
    Jackson, A. J. and Schumacher, H. J. (1980) Identification of urinary metabolites of EM12 N-(2’,6’dioxopiperiden-3’-yl)-phthalimidine, a teratogenic analog of thalidomide in rats and rabbits. Can. J. Pharm. Sci. 15, 21–23.Google Scholar
  37. 37.
    Heger, W., Schmahl, H. J., Klug, S., Felies, A., Nau, H., Merker, H. J., and Neubert, D. (1994) Embryotoxic effects of thalidomide derivatives in the non-human primate callithrix jacchus. IV. Teratogenicity of micrograms/kg doses of the EM 12 enantiomers. Teratog. Carcinog. Mutagen. 14,115–122.PubMedCrossRefGoogle Scholar
  38. 38.
    Fritz, M. B. (1966) Failure of thalidomide metabolites to produce malformations in the rabbit embryo. J. Reprod. Fert. 11, 157–159.CrossRefGoogle Scholar
  39. 39.
    Lucey, J. F. and Behrman, R. E. (1963) Thalidomide: effect upon pregnancy in the rhesus monkey. Science 139, 1295, 1296.Google Scholar
  40. 40.
    Turk, B. E., Jiang, H., and Liu, J. O. (1996) Binding of thalidomide to a 1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor a production. Proc. Natl. Acad. Sci. USA 93, 7552–7556.PubMedCrossRefGoogle Scholar
  41. 41.
    Gutman, M., Szold, A., Ravid, A., Lazzauskas, T., Merimsky, O., and Klausner, J. M. (1996) Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res. 16, 3673–3677.PubMedGoogle Scholar
  42. 42.
    Braun, A. G., Harding, A. G., and Weinreb, S. L. (1986) Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. Toxicol. Appl. Pharmacol. 31, 1637–1641.Google Scholar
  43. 43.
    Niwayama, S., Turk, B., and Liu, J. (1996) Potent inhibition of tumor necrosis factor-a production by tetrafluorothalidomide and tetrafluorophthalimides. J. Med. Chem. 39, 3044–3045.Google Scholar
  44. 44.
    Schroder, M., Risau, W., Hallman, R., Gautschi, P., and Bohlen, P. (1987) Tumor necrosis factor alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc. Natl. Acad. Sci. USA 84, 5277–5281.CrossRefGoogle Scholar
  45. 45.
    Smith, C., Friednash, M., Nguyen, C., Knauf, T., and Walsh, P. (1996) Failure of thalidomide as an antiangiogenesis factor in a murine melanoma model. J. Invest. Dermatol. 106, 845.Google Scholar
  46. 46.
    Ching, L.-M., Xu, Z.-F., Gummer, B. H., Palmer, B. D., Joseph, W. R., and Baguley, B. C. (1995) Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6dimethylxanthenone-4—acetic acid. Br. J. Cancer 72, 339–343.PubMedCrossRefGoogle Scholar
  47. 47.
    Nguyen, M., Tran, C., Barsky, S., Sun, J.-R., McBride, W., Pegram, M., Pietras, R., Love, S., and Glaspy, J. (1997) Thalidomide and chemotherapy combination: preliminary results of preclinical and clinical studies. Int. J. Oncol. 10, 965–969.PubMedGoogle Scholar
  48. 48.
    Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trazaskos, J. M., et al. (1996) Suppression of intestinal polyposis in APC del7l6 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87, 803–809.Google Scholar
  49. 49.
    Labayle, D., Fischer, D., Vielh, P., Drouhin, F., Pariente, A., Bories, C., Duhamel, O., Trousset, M., and Attali, P. (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101, 635–639.PubMedGoogle Scholar
  50. 50.
    Soler, R. A., Howard, M. A., Brink, N. S., Gibb, D., Tedder, R. S., and Nadal, D. (1996) Regression of AIDS-related Kaposi’s sarcoma during therapy with thalidomide. Clin. Inf. Dis. 23, 501–503.CrossRefGoogle Scholar
  51. 51.
    Sheskin, J. (1965) Further observation with thalidomide in lepra reactions. Lepr. Rev. 36, 183–187.PubMedGoogle Scholar
  52. 52.
    Jakeman, P. and Smith, W. C. S. (1994) Thalidomide in leprosy reaction. Lancet 343, 4332–433.CrossRefGoogle Scholar
  53. 53.
    Sampaio, E. P., Moreira, A. L., Sarno, E. N., Malta, A. M., and Kaplan, G. (1992) Prolonged treatment with recombinant interferon y induces erythema nodosum leprosum in lepromatous leprosy patients. J. Exp. Med. 175, 1729–173 7.Google Scholar
  54. 54.
    Kaplan, G. (1994) Cytokine regulation of disease progression in leprosy and tuberculosis. Immunobiology 191, 564–568.PubMedCrossRefGoogle Scholar
  55. 55.
    Field, E. O., Gibbs, J. E., Tucker, D. L., and Hellman, K. (1966) Effect of thalidomide on graft-versushost reaction. Nature 211, 1308–1310.PubMedCrossRefGoogle Scholar
  56. 56.
    Vogelsang, G. B., Farmer, E. R., Hess, A. D., Altamone, V., Beschoner, W. E., Jabs, D. A., Corio, R. L., Levin, L. S., Wingard, J. R., and Santos, G. W. (1992) Thalidomide for the treatment of chronic graftversus-host disease. N. Engl. J. Med. 326, 1055–1058.PubMedCrossRefGoogle Scholar
  57. 57.
    Parker, P. M., Chao, N., Nademanee, A., O’Donnell, M. R., Schmidt, G. M., Snyder, D. S., Stein, A. S., Smith, E. P., Molina, A., Stepan, D. E., et al. (1995) Thalidomide as salvage therapy for chronic graftversus-host disease. Blood 86, 3604–3609.PubMedGoogle Scholar
  58. 58.
    Vogelsang, G. B., Taylor, S., Gordon, G., and Hess, A. D. (1989) Thalidomide, a potent agent for the treatment of graft-versus-host disease. Transplant. Proc. 18, 904–906.Google Scholar
  59. 59.
    McCarthy, D. M., Kanfer, E. J., and Barrett, A. J. (1989) Thalidomide for the therapy of graft-versushost disease following allogeneic bone marrow transplantation. Biomed. Pharmacother. 43, 693–697.PubMedCrossRefGoogle Scholar
  60. 60.
    Ehninger, G., Eger, K., Stuhler, A., et al. (1993) Thalidomide—the need for a new clinical evaluation of an old drug. Bone Marrow Transplant. 12(Suppl.) 3, S26–S28.Google Scholar
  61. 61.
    Hamza, M. H. (1986) Treatment of Behcet’s disease with thalidomide. Clin. Rheumatol. 5, 365–371.PubMedCrossRefGoogle Scholar
  62. 62.
    Gutierrez-Rodriguez, O., Starusta-Bacal, P., and Gutierrez-Montes, O. (1989) Treatment of refractory rheumatoid arthritis—the thalidomide experience. J. Rheumatol. 16, 158–163.PubMedGoogle Scholar
  63. 63.
    Gutierrez-Rodriguez, O. (1984) Thalidomide. A promising new treatment for rheumatoid arthritis. Arthritis Rheum. 27, 1118–1121.PubMedCrossRefGoogle Scholar
  64. 64.
    Wettstein, A. R. and Meagher, A. P. (1997) Thalidomide in Crohn’s disease. Lancet 15, 1445, 1446.Google Scholar
  65. 65.
    Odeka, E. B. and Miller, V. (1997) Thalidomide in oral Crohn’s disease refractory to conventional medical treatment. J. Pediatr. Gastroenterol. Nutr. 25, 250, 251.Google Scholar
  66. 66.
    Ostraat, O. Ekberg, G., Schatz, H., Riesbeck, K., and Eriksson, T. (1992) Thalidomide prolongs graft survival in rat cardiac transplants. Transplant. Proc. 24 2624, 2625.Google Scholar
  67. 67.
    Ostraat, O., Riesbeck, K., Qi, Z., Eriksson, T., Schatz, H., and Ekberg, H. (1996) Thalidomide prolonged graft survival in a rat cardiac transplant model but had no inhibitory effect on lymphocyte function in vitro. Transpl. Immunol. 4, 117–125.PubMedCrossRefGoogle Scholar
  68. 68.
    Makonkawkeyoon, S., Limson-Pobre, R. N., Moreira, A. L., Schauf, V., and Kaplan, G. (1993) Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90, 5974–5978.PubMedCrossRefGoogle Scholar
  69. 69.
    Sampaio, E., Sarno, E., Lalilly, E., et al. (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173, 699–703.PubMedCrossRefGoogle Scholar
  70. 70.
    Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, A., Smith, K. A., and Kaplan, G. (1993) Thalidomide exerts its inhibitory action on tumor necrosis alpha (TNF-alpha) by enhancing mRNA degradation. J. Exp. Med. 177, 1675–1680.PubMedCrossRefGoogle Scholar
  71. 71.
    Balkwill, F. R. (1992) Tumour necrosis factor and cancer. Prog. Growth Factor Res. 4, 121–137.PubMedCrossRefGoogle Scholar
  72. 72.
    Kenyon, B., Voest, E., Chen, C., Flynn, E., Folkman, J., and D’Amato, R. J. (1996) A model of angiogenesis in the mouse cornea. Invest. Ophthalmol. Vis. Sci. 37, 1625–1631.PubMedGoogle Scholar
  73. 73.
    Yoshida, S., Ono, M., Shono, T., Izumi, H., Ishibashi, T., Suzuki, H., and Kuwano, M. (1997) Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor-dependent angiogenesis. Mol. Cell Biol. 17, 4015–4023.PubMedGoogle Scholar
  74. 74.
    Sunderkotter, C., Roth, J., and Sorg, C. (1990) Immunohistochemical detection of bFGF and TNF-alpha in the course of inflammatory angiogenesis in the mouse cornea. Am. J. Pathol. 137, 511–515.PubMedGoogle Scholar
  75. 75.
    Phillips, G. D. Stone, A. M., Jones, B. D., Schultz, J. C., Whitehead, R. A., and Knighton, D. R. (1994) Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo 8 961–965.Google Scholar
  76. 76.
    Mellin, G. W. and Katzenstein, N. (1962) The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital abnormalities. N. Engl. J. Med. 267, 1184–1193.PubMedCrossRefGoogle Scholar
  77. 77.
    Peacock, D. J., Banquerigo, M. L., and Brahn, E. (1992) Angiogenesis inhibition suppresses collagen arthritis. J. Exp. Med. 175, 1135.Google Scholar
  78. 78.
    Appleton, I., Brown, N. J., Willis, D., Colville-Nash, P. R., Alam, C., Brown, J. R., and Willoughby, D. A. (1996) The role of vascular endothelial growth factor in a murine chronic granulomatous tissue air pouch model of angiogenesis. J. Pathol. 180, 90–94.PubMedCrossRefGoogle Scholar
  79. 79.
    Colville-Nash, P. R., Alam, C. A. S., Appleton, I., Brown, J. R., Seed, M. P., and Willoughby, D. A. (1995) The pharmacological modulation of angiogenesis in chronic granulomatous inflammation. J. Pharmacol. Exp. Ther. 274, 1463–1472.Google Scholar
  80. 80.
    Nogueira, A. C., Neubert, R., Helge, H., and Neubert, D. (1994) Thalidomide and the immune system 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci. 55, 77–92.PubMedCrossRefGoogle Scholar
  81. 81.
    Neubert, R., Nogueira, A. C., and Neubert, D. (1993) Thalidomide derivatives and the immune system. I. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood. Arch. Toxicol. 67, 1–17.PubMedCrossRefGoogle Scholar
  82. 82.
    Nogueira, A. C., Neubert, R., Felies, A., Jacob-Muller, U., Frankus, E., and Neubert, D. (1996) Thalidomide derivatives and the immune system 6. Effects of two derivatives with no obvious teratogenic potency on the pattern of integrins and other surface receptors on blood cells of marmosets. Life Sci. 58, 337–348.PubMedCrossRefGoogle Scholar
  83. 83.
    Geitz, H., Handt, S., and Zwingenberger, K. (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31, 213–221.PubMedCrossRefGoogle Scholar
  84. 84.
    Sheppard, A. M., Onken, M. D., Rosen, G. D., Noakes, P. G., and Dean, D. C. (1994) Expanding roles for a4 integrin and its ligands in development. Cell Adhes. Commun. 2, 27–13.PubMedCrossRefGoogle Scholar
  85. 85.
    Brooks, P. C., Clark, R. A. F., and Cheresh, D. A. (1994) Requirement of vascular integrin avβ33 for angiogenesis. Science 264, 569–571.PubMedCrossRefGoogle Scholar
  86. 86.
    Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., and Cheresh, D. A. (1995) Definition of two angiogenic pathways by distinct av integrins. Science 270, 1500–1502.PubMedCrossRefGoogle Scholar
  87. 87.
    Brooks, P. C., Montgomery, A. M., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., and Cheresh, D. A. (1994) Integrin avβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157–1164.PubMedCrossRefGoogle Scholar
  88. 88.
    Yang, J. T., Rayburn, H., and Hynes, R. O. (1995) Cell adhesion events mediated by a4 integrins are essential in placental and cardiac development. Development 121, 549–560.Google Scholar
  89. 89.
    Drake, C. J., Cheresh, D. A., and Little, C. D. (1995) An antagonist of integrin avβ3 prevents maturation of blood vessels during embryonic neovascularization. J. Cell Sci. 108, 2655–2661.PubMedGoogle Scholar
  90. 90.
    Neubert, R., Hinz, N., Thiel, R., and Neubert, D. (1996) Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide. Life Sci. 58, 295–316.PubMedCrossRefGoogle Scholar
  91. 91.
    Klein, S., Giancotti, F. G., Presta, M., Albelda, S. M., Buck, C. A., and Rifkin, D. B. (1993) Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Mol. Biol. Cell 4, 973–982.PubMedGoogle Scholar
  92. 92.
    Enenstein, J., Waleh, N. S., and Kramer, R. H. (1992) Basic FGF and TGF-β differentially modulate integrin expression of human microvascular endothelial cells. Exp. Cell Res. 203, 499–503.PubMedCrossRefGoogle Scholar
  93. 93.
    Sepp, N. T., Li, L.-J., Lee, K. H., Brown, E. J., Caughman, S. W., Lawley, T. J., and Swerlick, R. A. (1994) Basic fibroblast growth factor increases expression of the avβ3 integrin complex on human microvascular endothelial cells. J. Invest. Dermatol. 103, 295–299.PubMedCrossRefGoogle Scholar
  94. 94.
    Senger, D. R., Ledbetter, S. R., Claffey, K. P., Papadopoulos-Sergiou, A., Perruzzi, C. A., and Detmar, M. (1996) Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the avβ3 integrin, osteopontin, and thrombin. Am. J. Pathol. 149, 293–305.PubMedGoogle Scholar
  95. 95.
    Friedlander, M., Theesfeld, C. L., Sugita, M., Fruttiger, M., Thomas, M. A., Chang, S., and Cheresh, D. A. (1996) Involvement of integrins avβ3 and avβ5 in ocularneovasculardiseases. Proc. Natl. Acad. Sci. USA 93,9764–9769.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Taturo Udagawa
  • Henk M. W. Verheul
  • Robert J. D’Amato

There are no affiliations available

Personalised recommendations